VSPharmTech selects Pharmaron and CRScube as partners for U.S. FDA phase 2 clinical trial

VSPharmTech Co., Ltd. (CEO Shin-Young Park) has selected global contract research organization (CRO) Pharmaron and digital clinical trial solution provider CRScube (CEO Ki-Don Kim) as partners for its U.S. FDA Phase 2 clinical trial of its radiation sensitizer candidate, VS-101.

VS-101, a drug designed to enhance the effectiveness of radiation therapy, is under development for a broad range of indications, including head and neck cancer, breast cancer, and glioblastoma. The Phase 2 trial in the U.S. will focus on head and neck cancer. Leveraging Pharmaron’s global clinical operations expertise and CRScube’s advanced digital solutions, the study is expected to be conducted especially efficiently and with high precision.

Pharmaron, which will lead clinical operations, is a global CRO established in 2004 that provides end-to-end services for drug development, including R&D, manufacturing, and clinical trials. With key hubs in the U.S., UK, and China, the company has over 25,000 employees offering integrated services to pharmaceutical and biotech firms worldwide.

Lee Doo-Jin, Country Manager of Pharmaron Korea, commented, “VSPharmTech has strategically collaborated with Pharmaron from preclinical trials to clinical drug manufacturing and U.S. clinical trials, successfully addressing time, cost, and quality all at once. We will leverage Pharmaron’s global network and clinical trial experience to ensure the success of this Phase 2 trial.”

CRScube will provide its unified platform, including cubeCDMS (EDC), cubeIWRS (RTSM), and cubeSAFETY (Safety database), for clinical data capture and data management, randomization and inventory management, and pharmacovigilance. These solutions, recognized for their user-friendliness and data reliability, have been used in over 5,900 clinical trials across more than 30 countries.

Ki-Don Kim, CEO of CRScube, stated, “The use of CRScube’s solutions in this project is a testament to our proven technology and reliability in global clinical trials. We are committed to delivering efficient data management and stable service throughout the trial.”

Shin-Young Park, CEO of VSPharmTech, said, “This collaboration with Pharmaron and CRScube is a key opportunity to enhance our competitiveness in global clinical trials and increase the likelihood of success. We will do our utmost to deliver innovative therapeutics to patients through this trial.”

This three-party collaboration is expected to strengthen VSPharmTech’s competitiveness in global drug development and accelerate efforts to attract further investment.

About VSPharmTech

VSPharmTech is a biotech company dedicated to developing innovative therapeutics that enhance the effectiveness of radiation therapy. Targeting global markets, the company is advancing a diverse pipeline of new drugs, including the radiation sensitizer VS-101, with a focus on rapid clinical development and strategic partnerships with global pharmaceutical companies to bring transformative therapies to market.

About Pharmaron

Founded in 2004, Pharmaron is a global CRO offering end-to-end services for drug development, including R&D, manufacturing, and clinical trials. With over 25,000 employees across major hubs such as the U.S., UK, and China, Pharmaron provides integrated services to global pharmaceutical and biotech companies. The Korea branch, established in 2021, supports domestic companies in new drug development and global market expansion.

About CRScube

CRScube is a specialized provider of clinical trial software solutions. Since its founding in 2010, the company has developed comprehensive software systems covering the full clinical trial process, from study design and data collection to safety reporting, trial operations, and risk-based monitoring. Its unified eClinical platform complies with FDA 21 CFR Part 11 and has been actively used in over 5,900 clinical trials across 30 countries in Asia, North America, Europe, and Africa.